The Democratic Republic of Congo (DRC) and neighboring Uganda are currently grappling with a concerning new health crisis: an outbreak of Ebola disease caused by the less common Bundibugyo virus. On May 15, 2026, the DRC’s Ministry of Health officially declared the outbreak in the country’s northeast, where teams from Médecins Sans Frontières (MSF) are actively engaged in response efforts. Since this declaration, nearly 500 suspected cases and over 130 deaths have been reported across multiple health zones within the DRC. The same day, Uganda confirmed that the virus had crossed its border, indicating a significant regional spread. This particular outbreak presents a unique challenge because the Bundibugyo virus, unlike the more common Zaire Ebola virus, currently lacks an approved vaccine or specific treatment. This critical distinction means that healthcare providers and public health officials must rely on a different set of strategies to contain the disease and support those affected, making the response particularly complex and urgent. ## The Bundibugyo Challenge: A Distinct Form of Ebola Ebola Viral Disease (EVD) is a severe, often fatal illness in humans and other primates. It is caused by several species of Ebolavirus, with the Zaire Ebolavirus being the most well-known due to its involvement in major outbreaks, including the devastating West Africa epidemic from 2014 to 2016. However, this current outbreak is attributed to the Bundibugyo virus, a rarer strain that poses distinct challenges for medical response. While sharing similar severe symptoms with other Ebola strains, such as fever, intense weakness, muscle pain, headache, and sore throat, followed by vomiting, diarrhea, rash, and internal and external bleeding, the Bundibugyo virus requires specific medical countermeasures. Historical data from previous Bundibugyo outbreaks indicate a case fatality rate ranging from 25% to 40%, underscoring its potential severity. Understanding these differences is crucial for scientists and clinicians working to develop and deploy effective tools against this specific threat. ## No Approved Vaccines or Specific Treatments Yet One of the most pressing concerns in the current situation is the absence of targeted medical interventions. While there are two approved vaccines for Ebola, including the widely used Ervebo (rVSV-ZEBOV) vaccine, these have been developed and approved specifically for the Zaire Ebolavirus. They are effective in limiting the spread of Zaire Ebola through strategies like ring vaccination, where contacts of infected individuals, their contacts, and frontline healthcare workers are immunized. Unfortunately, these existing vaccines do not provide protection against the Bundibugyo virus. Similarly, specific treatments, such as the monoclonal antibodies developed and licensed following clinical trials for Zaire Ebola in the DRC between 2018 and 2020, are also ineffective against the Bundibugyo strain. While experimental antiviral candidates and monoclonal antibodies do exist for Bundibugyo, their efficacy has not yet been definitively established or approved for widespread use. This gap highlights the significant hurdles in combating rarer disease strains. Developing and testing new vaccines and treatments is a rigorous, time-consuming process. Discussions are currently underway within the World Health Organization (WHO) to explore potential vaccine candidates that could be tested in emergency clinical trials, mirroring successful efforts in previous Ebola outbreaks. Organizations like MSF have expressed readiness to contribute to this vital research, drawing on their experience in past trials that led to the approval of current Ebola vaccines and treatments. ## The Critical Role of Supportive Care In the absence of a specific vaccine or antiviral treatment, the cornerstone of care for patients with Bundibugyo virus infection is intensive supportive therapy. This approach focuses on managing symptoms and bolstering the patient's own immune response to fight the virus, thereby improving their chances of survival. This includes meticulous fluid replacement to combat severe dehydration caused by vomiting and diarrhea, oxygen support for those experiencing respiratory distress, and close monitoring of vital signs such as blood pressure, heart rate, and blood parameters. Care teams also provide medication for pain relief, fever reduction, and to manage other symptoms like nausea. Such comprehensive supportive care, administered in specialized Ebola treatment centers, can significantly reduce the severity of the illness and prevent complications, even without a specific cure for the virus itself. This demanding work underscores the dedication and expertise of healthcare workers on the front lines. ## Diagnostic Challenges Slowing Response Adding another layer of complexity to the response is the challenge of rapid and accurate diagnosis. While Polymerase Chain Reaction (PCR) tests are the gold standard for confirming Ebola infections, they require virus-specific diagnostic cartridges. For the Bundibugyo virus, these specialized cartridges are currently in critically short supply. This scarcity considerably slows down the confirmation of cases, creating delays that have cascading effects on outbreak control. Delayed diagnosis means that infected individuals may remain in their communities longer, potentially spreading the virus to more people. It also hampers effective contact tracing, the process of identifying and monitoring everyone who has come into contact with an infected person. Without swift confirmation, isolating patients and tracing their contacts becomes a much more difficult and less effective endeavor, allowing the virus to gain a foothold and spread further within communities. ## Containing the Spread Without Specific Tools Given the lack of approved vaccines or treatments, the core strategy for limiting the Bundibugyo virus's spread relies heavily on established epidemiological and public health measures. These are tried-and-true methods that have proven effective in controlling past outbreaks of various infectious diseases. Key actions include: early isolation of suspected and confirmed cases in dedicated treatment facilities; rigorous daily monitoring of contacts for 21 days, with immediate quarantine if symptoms emerge; strict infection prevention and control (IPC) protocols in all healthcare settings, encompassing meticulous hand hygiene, proper waste management, access to chlorinated water points, and consistent use of personal protective equipment (PPE) by all healthcare workers. Additionally, safe and dignified burials are paramount to prevent transmission during funeral rituals, which have historically been significant drivers of Ebola spread. On-the-ground epidemiological work to reconstruct transmission chains and identify high-risk practices is also essential for understanding and interrupting spread patterns. Crucially, maintaining access to non-Ebola-related healthcare for people in affected areas is vital to prevent secondary health crises. ## The Indispensable Role of Community Engagement None of these public health measures can succeed without the active and sustained engagement of the affected communities. Informing people accurately, building trust, and fostering their cooperation are critical. This task becomes significantly more challenging in regions marked by insecurity, limited access to healthcare, and a history of mistrust in external interventions—conditions unfortunately prevalent in some of the DRC provinces currently affected by this outbreak. Engaging local leaders, understanding cultural practices, and tailoring health messages to local contexts are essential. When communities feel involved and understand the reasons behind public health measures, they are more likely to adhere to them, such as reporting symptoms early, cooperating with contact tracers, and adopting safe practices. Without this crucial buy-in, even the most robust public health plans can falter. ## A History of Outbreaks and Global Vigilance This is not the first time the DRC has faced an Ebola outbreak; it marks the country's seventeenth such event since the virus was first identified in 1976. Specifically, this is the third known outbreak involving the Bundibugyo virus, following incidents in Uganda (2007–2008) and the DRC (2012). Organizations like MSF have extensive experience responding to multiple Ebola crises globally, including major outbreaks in West Africa and previous ones in DRC and Uganda, which equips them with invaluable knowledge and expertise. The urgency of the current response is underscored by the fact that over 50 people had already died since early April, even before the official declaration of the outbreak on May 15. This delayed detection is a concerning sign, often characteristic of the early stages of Ebola outbreaks, but particularly worrying given the high number of suspected cases and deaths already announced. This situation highlights the importance of strengthening surveillance systems and rapid response capabilities, not only in affected countries but globally, to prevent such outbreaks from escalating into wider humanitarian crises. Looking ahead, sustained international support, rapid research into Bundibugyo-specific countermeasures, and continued on-the-ground efforts in community engagement and public health are essential to control this evolving threat and protect populations in the DRC, Uganda, and beyond. The world remains vigilant as health authorities and humanitarian organizations work tirelessly to bring this challenging outbreak under control.